Daiwa Securities Group Inc. cut its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 34.5% during the second quarter, Holdings Channel reports. The firm owned 3,980 shares of the medical instruments supplier’s stock after selling 2,100 shares during the period. Daiwa Securities Group Inc.’s holdings in C.R. Bard were worth $1,258,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SRS Capital Advisors Inc. boosted its position in C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares during the period. Creative Planning boosted its position in C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock valued at $1,068,000 after buying an additional 29 shares during the period. Blair William & Co. IL boosted its position in C.R. Bard by 0.9% in the first quarter. Blair William & Co. IL now owns 3,492 shares of the medical instruments supplier’s stock valued at $865,000 after buying an additional 30 shares during the period. First Merchants Corp boosted its position in C.R. Bard by 0.6% in the second quarter. First Merchants Corp now owns 5,135 shares of the medical instruments supplier’s stock valued at $1,623,000 after buying an additional 32 shares during the period. Finally, Pennsylvania Trust Co boosted its position in C.R. Bard by 2.9% in the first quarter. Pennsylvania Trust Co now owns 1,240 shares of the medical instruments supplier’s stock valued at $308,000 after buying an additional 35 shares during the period. Institutional investors own 85.32% of the company’s stock.

C.R. Bard, Inc. (BCR) opened at 318.63 on Thursday. The firm has a market cap of $23.16 billion, a PE ratio of 41.83 and a beta of 0.59. The company’s 50-day moving average is $318.77 and its 200 day moving average is $282.55. C.R. Bard, Inc. has a one year low of $203.63 and a one year high of $323.27.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The business had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. During the same quarter last year, the firm posted $2.54 EPS. C.R. Bard’s revenue was up 5.2% compared to the same quarter last year. Equities analysts anticipate that C.R. Bard, Inc. will post $11.83 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were given a $0.26 dividend. This represents a $1.04 annualized dividend and a yield of 0.33%. The ex-dividend date of this dividend was Thursday, July 20th. C.R. Bard’s payout ratio is currently 13.67%.

TRADEMARK VIOLATION WARNING: This story was first reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/08/10/c-r-bard-inc-bcr-shares-sold-by-daiwa-securities-group-inc.html.

Several research firms have recently weighed in on BCR. Zacks Investment Research upgraded shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price target for the company in a report on Tuesday, June 13th. BMO Capital Markets cut shares of C.R. Bard from an “outperform” rating to a “market perform” rating and set a $245.00 price target for the company. in a report on Tuesday, April 25th. Morgan Stanley cut shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a report on Monday, April 24th. BidaskClub cut shares of C.R. Bard from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Finally, Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $285.67.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.